Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis (NCT02473601) | Clinical Trial Compass
UnknownPhase 2
Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis
China80 participantsStarted 2014-10
Plain-language summary
Observed the muscle relaxation of mivacurium in patients with liver cirrhosis.Clear of mivacurium in patients with liver cirrhosis without muscle relaxant accumulation and delayed recovery phenomenon
Who can participate
Age range18 Years – 60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients volunteered for the clinical research and signed a written informed consent
* Experimental group patients is cirrhosis of the liver (liver function grade Child - Pugh, grade A) ready to abdominal surgery patients; The control group was no cirrhosis, ready to abdominal surgery patients
* Aged 18 \~ 60
* BMI\<28kg/㎡
* The American society of anesthesiologists (ASA) class I \~ II
Exclusion Criteria:
* Systolic blood pressure ≥180 mm Hg or \< 90 mm Hg, diastolic blood pressure ≥110 mm Hg or \< 60 mm Hg
* Serious heart, brain, liver, kidney, lung, endocrine diseases or serious infection
* Patients with difficult airway (such as Mallampati airway class III, airway abnormalities, etc.)
* HR \< 50 times/min
* The patient had a history of mental illness or chronic psychiatric drugs, chronic pain medication history
* History of alcoholism
* Patients with neuromuscular system disease
* Has a tendency to malignant hyperthermia
* The patient used to test drug allergies or other contraindications
* Over the past 30 days participated in other clinical drug research
What they're measuring
1
TOF ratio
Timeframe: Time from administration to TOF (T4/T1) values recovered to 90%,an expected average of 25-30 minutes